In summary, the present data indicated that ASP enhanced both renal and hepatic EPO production via stabilizing HIF-2α protein and attenuating inflammatory suppression, restored EPOR signaling systems, and increased iron availability by suppressing hepcidin and inflammation, thereby correcting anemia in CKD rats (Figure 9). The gene discussed is EPO; the disease is anemia.